CERC - セレコ― （Cerecor Inc.） セレコ―CERCのチャート
CERCの企業情報
| symbol | CERC |
|---|---|
| 会社名 | Cerecor Inc （セレコ―） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 Cerecor Inc. is a clinical stage biopharmaceutical company. The Company is engaged in developing drug candidates for patients with neurological and psychiatric disorders. The Company has a portfolio of clinical and preclinical compounds that it is developing for a range of indications including CERC-301 which is an adjunctive treatment for major depressive disorder (MDD); CERC-501 which is for substance use disorders and adjunctive treatment of MDD and CERC-406 which is for the treatment of cognitive impairment. The Company owns the rights to its COMTi platform. Catechol O methyltransferase (COMT) is an enzyme critical for the inactivation and metabolism of dopamine and its inhibition in the brain has applicability in treating subjects with neuropsychiatric conditions including MDD schizophrenia Parkinson''s disease and pathological gambling. Its COMTi platform comprises COMT inhibitors with selectivity for membrane bound COMT which is the dominant form of COMT. セレコ―は米国の臨床段階のバイオ医薬品会社。神経障害や精神疾患の治療薬の開発に重点を置く。主要候補薬には、大鬱病性障害(MDD)の補助的治療薬の「CERC-301」、大鬱病性障害や物質使用障害の補助的治療薬「CERC-501」、後遺認知障害症のための「CERC-406」がある。本社はメリ―ランド州ボルチモア。 Cerecor is a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare and orphan diseases. The company is advancing its clinical-stage pipeline of innovative therapies that address unmet patient needs within rare and orphan diseases. The company's rare disease pipeline includes CERC-801, CERC-802 and CERC-803, which are in development for congenital disorders of glycosylation and CERC-006, an oral mTORc1/c2 inhibitor in development for the treatment of complex lymphatic malformations. The company is also developing two monoclonal antibodies, CERC-002, and CERC-007. CERC-002 targets the cytokine LIGHT (TNFSF14) and is in clinical development for treatment of severe pediatric-onset Crohn's disease, and COVID-19 acute respiratory distress syndrome. CERC-007 targets the cytokine IL-18 and is in clinical development for the treatment of Still's disease (adult onset Still's disease (AOSD) and systemic juvenile idiopathic arthritis (sJIA)), and multiple myeloma (MM). CERC-006, 801, 802 and 803 have all received Orphan Drug Designation and Rare Pediatric Disease Designation, which makes all four eligible for a priority review voucher upon FDA approval. |
| 本社所在地 | 400 E. Pratt Street Suite 606 Baltimore MD 21202 USA |
| 代表者氏名 | Uli Hacksell ウリ・ハッスル |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +1 410-522-8707 |
| 設立年月日 | 40544 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | 2015年 |
| 従業員数 | － |
| url | www.cerecor.com |
| nasdaq_url | https://www.nasdaq.com/symbol/cerc |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） 14.46257 |
| 終値（lastsale） | 4.39 |
| 時価総額（marketcap） | 174191270.95 |
| 時価総額 | 時価総額（百万ドル） 183.87190 |
| 売上高 | 売上高（百万ドル） 36.53905 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 197.11869 |
| 当期純利益 | 当期純利益（百万ドル） 7.93865 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Cerecor Inc revenues increased from $542K to $9.3M. Net loss increased from $3.8M to $9.9M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Change in fair value of warrant increase from $2K to $295K (expense) Interest expense net increase from $83K to $343K (expense). |
CERCのテクニカル分析
CERCのニュース
Sara-Bay Financial Buys Ranpak Holdings Corp, Cerecor Inc, Apple Inc, Sells RealPage Inc, ... 2021/07/16 20:38:02 GuruFocus
Related Stocks: BAC , WELL , PACK , CERC , AAPL , TRI , ALLY , MRO , PRAH , RP , CRNC , ATSG , STX , IPHI , TAL ,
Centre pushes back against CERC order allowing discoms to exit PPAs 2021/07/06 16:31:49 The Hindu BusinessLine
Provides discoms the right to also restructure their agreements
Power Play: Govt may not allow BSES to exit PPA with NTPC 2021/07/05 23:10:00 The Financial Express
The right to allocate or de-allocate power from plants owned by CPSEs lies with the Central government, so the CERC order can take effect only with its consent.
India: Projects, Energy & Infrastructure Monthly Newsletter | June 2021 - HSA Advocates 2021/07/05 08:37:11 Mondaq
CERC notifies the Draft of Central Electricity Regulatory Commission (Ancillary Services) Regulations, 2021.
Discoms can terminate power purchase agreements after 25 years 2021/07/05 08:05:30 Sify.com
New Delhi: In a major relief for power distribution companies, the Central Electricity Regulatory Commission (CERC) has said that discoms are eligible to terminate power purchase agreements (PPA) after 25 years of operations. In a case pertaining to BSES Yamuna Power Ltd, the power regulator has ordered the BSES discom to exit the PPA with NTPC''s Dadri-I power generating station. "We are of the view that in terms of the PPA and the SPPA and the fact that Dadri-I generating station having completed 25 years on November 30, 2020, the petitioners are eligible to exercise the first right of refusal as per provisions of Regulation 17(2) of the 2019 Tariff Regulations," the order said. It also said that the Centre''s guidelines also permit the willing distribution companies to relinquish their allocation after a period of 25 years from Commercial Operation Date (COD). It noted that the Delhi Electricity Regulatory Commission (DERC) has already written to Ministry of Power for de-allocation of share of distribution companies of Delhi.
Thinking about buying stock in Cerecor, Surface Oncology, SINTX Technologies, Clearpoint Neuro, or Senseonics Holdings? 2021/03/02 14:31:00 PR Newswire
NEW YORK, March 2, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CERC, SURF, SINT, CLPT, and SENS. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….
Cerecor Announces CERC-002 Significantly Reduced Respiratory Failure and Mortality in Phase 2 Clinical Trial in Patients Hospitalized with COVID-19 ARDS 2021/03/02 12:00:00 GlobeNewswire
Final analysis inclusive of the 60-day safety update in the randomized placebo-controlled study demonstrated CERC-002 was statistically significant in…
Power Ministry reduces discom penalties to 5% over SBI lending rate 2021/02/24 08:55:38 Economic Times India
The government has lowered the late payment fee chargeable by power and transmission developers from distribution companies by linking it to State Bank of India's lending rate against the current 18%.The Electricity (Late Payment Surcharge) Rules 2021 exclude existing power plants and transmission systems whose tariffs have been determined through competitive bidding.The rules bar electricity distribution companies with any outstanding bills after seven months from due date from procuring power from power exchanges or grant of short -term open access. The rules came into force on Monday when they were notified.The gazette notification issued by the power ministry evoked mixed response from the industry as it supersedes regulations of the Central Electricity Regulatory Commission (CERC) and also the power purchase/transmission agreements. CERC chairperson P K Pujari had in October sent a statutory advice to the government against issuance of the rules citing jurisdictional overlap.The power distribution companies welcomed reduction in late payment fee while electricity generation plants and transmission companies with regulated tariffs said lowering of the penalty rates interest would discourage timely payments by states.
The Daily Biotech Pulse: Aridis To Study Antibody Cocktail For Coronavirus Variants, Revance & Protalix Data Readouts 2021/02/23 12:25:48 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 22) Acceleron Pharma Inc (NASDAQ: XLRN ) Akari Therapeutics PLC (NASDAQ: AKTX ) Annexon Inc (NASDAQ: ANNX ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) AxoGen, Inc (NASDAQ: AXGN ) Burning Rock Biotech Ltd (NASDAQ: BNR ) Celcuity Inc (NASDAQ: CELC ) (announced a $20 million common stock offering) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Cerecor Inc (NASDAQ: CERC ) Citius Pharmaceuticals Inc (NASDAQ: CTXR ) DermTech Inc (NASDAQ: DMTK ) Gemini Therapeutics Inc (NASDAQ: GMTX ) Intra-Cellular Therapies Inc (NASDAQ: ITCI ) (announced NDA submissions for two indications for Caplyta - as monotherapy and as adjunctive therapy with lithium or valproate for the treatment of depressive episodes associated with bipolar I or II disorder) iTeos Therapeutics Inc (NASDAQ: ITOS ) Mereo BioPharma Group plc – ADR (NASDAQ: MREO ) Nantkwest Inc (NASDAQ: NK ) Orthofix Medical Inc (NASDAQ: OFIX ) PAVmed Inc (NASDAQ: PAVM ) (reacted to its fourth-quarter results) Pharvaris BV (NASDAQ: PHVS ) Pliant Therapeutics Inc (NASDAQ: PLRX ) RedHill Biopharma Ltd (NASDAQ: RDHL ) Silence Therapeutics ADR Representing 3 Ord Shs (NASDAQ: SLN ) United Therapeutics Corporation (NASDAQ: UTHR ) Vistagen Therapeutics Inc (NASDAQ: VTGN ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Feb. 22) bluebird bio Inc (NASDAQ: BLUE ) Pharming Group (NASDAQ: PHAR ) Talis Biomedical Corp (NASDAQ: TLIS ) Vallon Pharmaceuticals Inc (NASDAQ: VLON ) Stocks In Focus Surface Oncology Exercises Option to License Vaccinex Platform-discovered Anti-CCR8 Antibody Vaccinex Inc (NASDAQ: VCNX ) announced that Surface Oncology Inc (NASDAQ: SURF ) will be exercising its option to license the anti-CCR8 antibody discovered via Vaccinex's ActivMAb antibody discovery and novel viral display platform.
CERC norms: ‘Market coupling’ mechanism for spot power market gets a leg-up 2021/02/18 23:45:00 The Financial Express
Analysts said the new regulations will help increase the share of spot power in electricity purchased by discoms and large industrial consumers.
Thinking about buying stock in Cerecor, Surface Oncology, SINTX Technologies, Clearpoint Neuro, or Senseonics Holdings? 2021/03/02 14:31:00 PR Newswire
NEW YORK, March 2, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CERC, SURF, SINT, CLPT, and SENS. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….
Cerecor Announces CERC-002 Significantly Reduced Respiratory Failure and Mortality in Phase 2 Clinical Trial in Patients Hospitalized with COVID-19 ARDS 2021/03/02 12:00:00 GlobeNewswire
Final analysis inclusive of the 60-day safety update in the randomized placebo-controlled study demonstrated CERC-002 was statistically significant in…
Power Ministry reduces discom penalties to 5% over SBI lending rate 2021/02/24 08:55:38 Economic Times India
The government has lowered the late payment fee chargeable by power and transmission developers from distribution companies by linking it to State Bank of India's lending rate against the current 18%.The Electricity (Late Payment Surcharge) Rules 2021 exclude existing power plants and transmission systems whose tariffs have been determined through competitive bidding.The rules bar electricity distribution companies with any outstanding bills after seven months from due date from procuring power from power exchanges or grant of short -term open access. The rules came into force on Monday when they were notified.The gazette notification issued by the power ministry evoked mixed response from the industry as it supersedes regulations of the Central Electricity Regulatory Commission (CERC) and also the power purchase/transmission agreements. CERC chairperson P K Pujari had in October sent a statutory advice to the government against issuance of the rules citing jurisdictional overlap.The power distribution companies welcomed reduction in late payment fee while electricity generation plants and transmission companies with regulated tariffs said lowering of the penalty rates interest would discourage timely payments by states.
The Daily Biotech Pulse: Aridis To Study Antibody Cocktail For Coronavirus Variants, Revance & Protalix Data Readouts 2021/02/23 12:25:48 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 22) Acceleron Pharma Inc (NASDAQ: XLRN ) Akari Therapeutics PLC (NASDAQ: AKTX ) Annexon Inc (NASDAQ: ANNX ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) AxoGen, Inc (NASDAQ: AXGN ) Burning Rock Biotech Ltd (NASDAQ: BNR ) Celcuity Inc (NASDAQ: CELC ) (announced a $20 million common stock offering) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Cerecor Inc (NASDAQ: CERC ) Citius Pharmaceuticals Inc (NASDAQ: CTXR ) DermTech Inc (NASDAQ: DMTK ) Gemini Therapeutics Inc (NASDAQ: GMTX ) Intra-Cellular Therapies Inc (NASDAQ: ITCI ) (announced NDA submissions for two indications for Caplyta - as monotherapy and as adjunctive therapy with lithium or valproate for the treatment of depressive episodes associated with bipolar I or II disorder) iTeos Therapeutics Inc (NASDAQ: ITOS ) Mereo BioPharma Group plc – ADR (NASDAQ: MREO ) Nantkwest Inc (NASDAQ: NK ) Orthofix Medical Inc (NASDAQ: OFIX ) PAVmed Inc (NASDAQ: PAVM ) (reacted to its fourth-quarter results) Pharvaris BV (NASDAQ: PHVS ) Pliant Therapeutics Inc (NASDAQ: PLRX ) RedHill Biopharma Ltd (NASDAQ: RDHL ) Silence Therapeutics ADR Representing 3 Ord Shs (NASDAQ: SLN ) United Therapeutics Corporation (NASDAQ: UTHR ) Vistagen Therapeutics Inc (NASDAQ: VTGN ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Feb. 22) bluebird bio Inc (NASDAQ: BLUE ) Pharming Group (NASDAQ: PHAR ) Talis Biomedical Corp (NASDAQ: TLIS ) Vallon Pharmaceuticals Inc (NASDAQ: VLON ) Stocks In Focus Surface Oncology Exercises Option to License Vaccinex Platform-discovered Anti-CCR8 Antibody Vaccinex Inc (NASDAQ: VCNX ) announced that Surface Oncology Inc (NASDAQ: SURF ) will be exercising its option to license the anti-CCR8 antibody discovered via Vaccinex's ActivMAb antibody discovery and novel viral display platform.